Core Points - Zhejiang Xianju Pharmaceutical Co., Ltd. has received an administrative regulatory measure from the China Securities Regulatory Commission due to issues related to the management and use of raised funds [1][2] - The company has previously faced penalties for price monopoly related to the raw material dexamethasone phosphate sodium [5][6] Fund Management Issues - The Zhejiang Securities Regulatory Bureau found that Xianju Pharmaceutical had not followed proper procedures for the review and disclosure of certain raised funds, used raised funds for unrelated expenses, and mixed raised funds with its own funds when purchasing structured deposit financial products [2][3] Regulatory Actions - The regulatory measures include warning letters issued to the company and key personnel, including the chairman, general manager, financial director, and board secretary, which will be recorded in the securities and futures market integrity archives [3] Impact on Operations - Xianju Pharmaceutical stated that the administrative regulatory measures will not affect its normal production and business activities, and the company will comply with legal and regulatory requirements for timely information disclosure [4] Previous Penalties - Earlier in the year, Xianju Pharmaceutical was fined a total of 195 million yuan for engaging in price-fixing agreements that violated anti-monopoly laws, with the fine amounting to 4.88% of the company's audited revenue and 49.17% of its net profit attributable to shareholders for 2024 [5][6] Financial Performance - The company has experienced a decline in revenue and net profit in recent years, with revenues of 4.123 billion yuan and 4.001 billion yuan for 2023 and 2024, respectively, representing year-on-year declines of 5.85% and 2.98% [7] - In the first half of 2025, the company reported revenues of 1.869 billion yuan, a year-on-year decrease of 12.56%, with net profit attributable to shareholders at 308 million yuan, down 9.26% [7]

证券代码：002332 证券简称：仙琚制药 公告编号：2025-040 浙江仙琚制药股份有限公司 关于公司及相关人员收到浙江证监局 警示函的公告 登录新浪财经APP 搜索【信披】查看更多考评等级 浙江仙琚制药股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 浙江仙琚制药股份有限公司（以下简称"公司"）于近日收到中国证券监督管理委员会浙江监管局（以下 简称"浙江证监局"）出具的行政监管措施决定书《关于对浙江仙琚制药股份有限公司及相关人员采取出 具警示函措施的决定》〔2025〕210号）（以下简称"《决定书》"）。现将相关情况公告如下： 一、《决定书》的主要内容 浙江证监局在现场检查中发现浙江仙琚制药股份有限公司（以下简称公司）募集资金管理和使用方面存 在以下问题:部分募集资金置换未按规定履行审议程序并披露，使用募集资金支付与募投项目无关的部 分费用，使用闲置募集资金购买银行结构性存款理财产品时存在募集资金与自有资金混同的情形。 公司上述行为违反了《上市公司信息披露管理办法》(证监会令第182号)第三条第一款，《上市公司监 管指引第2号--上市公司募集 ...

Core Points - The company, Xianju Pharmaceutical, has received approval from the National Medical Products Administration for the registration of Estradiol Tablets [2] Group 1 - The approval includes the issuance of a Drug Registration Certificate with the number 2025S02904 [2]

Core Viewpoint - Xianju Pharmaceutical has received approval from the National Medical Products Administration for the registration of its estradiol tablets, which is a significant milestone for the company [1] Company Summary - Xianju Pharmaceutical's revenue composition for the first half of 2025 shows that pharmaceuticals account for 99.34% of total revenue, while other businesses contribute only 0.66% [1] - As of the report date, Xianju Pharmaceutical has a market capitalization of 9.9 billion yuan [1]

格隆汇9月19日丨仙琚制药(002332.SZ)公布，近日收到国家药品监督管理局核准签发的关于雌二醇片的 《药品注册证书》，公司雌二醇片被批准注册。雌二醇片，规格为1mg，参比制剂为美国上市的雌二醇 片（商品名：ESTRADIOL）。雌二醇片参比制剂由BARRLABORATORIESINC开发，于1997年10月22 日被美国FDA批准上市。雌二醇片的适应症为用于雌激素缺乏引起的相关疾病，同时可以预防骨质疏 松。 ...

仙琚制药（002332）(002332.SZ)公告，公司近日收到国家药品监督管理局核准签发的关于雌二醇片的 《药品注册证书》，公司雌二醇片被批准注册。雌二醇片的适应症为用于雌激素缺乏引起的相关疾病， 同时可以预防骨质疏松。 ...

人民财讯9月19日电，仙琚制药（002332）9月19日公告，近日收到国家药品监督管理局核准签发的关于 雌二醇片的《药品注册证书》，公司雌二醇片被批准注册。 ...

格隆汇9月19日｜近日，浙江仙琚制药股份有限公司收到国家药监局核准签发的雌二醇片《药品注册证 书》。该药品规格为1mg，剂型为片剂，注册分类属化学药品4类，批准文号为国药准字H20255491。其 参比制剂1997年10月22日获美国FDA批准上市，适应症为雌激素缺乏相关疾病及预防骨质疏松。此次获 批有利于丰富公司产品线、提升竞争力，但药品研发等受政策和市场等因素影响，存不确定性，公司提 醒投资者注意风险。 ...

格隆汇9月19日丨仙琚制药(002332.SZ)公布，近日收到国家药品监督管理局核准签发的关于雌二醇片的 《药品注册证书》，公司雌二醇片被批准注册。雌二醇片，规格为1mg，参比制剂为美国上市的雌二醇 片（商品名：ESTRADIOL）。雌二醇片参比制剂由BARRLABORATORIESINC开发，于1997年10月22 日被美国FDA批准上市。雌二醇片的适应症为用于雌激素缺乏引起的相关疾病，同时可以预防骨质疏 松。 ...

智通财经APP讯，仙琚制药(002332.SZ)公告，公司近日收到国家药品监督管理局核准签发的关于雌二醇 片的《药品注册证书》，公司雌二醇片被批准注册。雌二醇片的适应症为用于雌激素缺乏引起的相关疾 病，同时可以预防骨质疏松。 ...